Press Releases

Date Title
Feb 29, 2024 Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 – – Phase 2 ONC201 Data Published in Peer-Reviewed Journal of Clinical Oncology – – $204 Million in Cash and Equivalents at December 31, 2023 – – Conference Call at 8:30 a.m.
Feb 27, 2024 Chimerix to Present at TD Cowen 44th Annual Health Care Conference
DURHAM, N.C. , Feb. 27, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole , Chief Executive Officer, will
Feb 22, 2024 Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024
DURHAM, N.C. , Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on
Displaying 11 - 13 of 13
  • Print
  • Email Alerts
  • RSS Feeds
  • Search
  • Share
scroll back to top of page